North America Active Pharmaceutical Ingredients (API) Market 2021-2027 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application

PrintEmail
Feb 2021 - 161 Pages - From $2,480
(Excel Data Sheet: $1,500)
Description

The report cover may be different from the image shown.

  • The product will be delivered as a PDF file by Email within 48 business hours upon receiving an order. 
  • To learn more about the report, please Download Free Sample Pages and Download Excel Datasheet Sample. The report will be updated before delivery, so that the most recent historic year is the base year and forecast covers 5-10 years over the base year.
  • PleaseContact Us for any question, custom research, and current discount. It is possible now to buy a part of the report such as chapters, sections, data tables or figures.
Product and Price

By clicking the Add to Shopping Cart button, you certify to agree with our Terms of Service.

North America active pharmaceutical ingredients (API) market is expected to grow by 5.5% annually in the forecast period and reach $106.28 billion by 2027 owing to the rising need for medicine and pharmaceutical agents amid the COVID-19 pandemic.
Highlighted with 90 tables and 64 figures, this 161-page report “North America Active Pharmaceutical Ingredients (API) Market 2021-2027 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2020 and provides forecast from 2021 till 2027 with 2020 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.

Based on Synthesis, the North America market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.
Synthetic API
• Branded Synthetic API
• Generic Synthetic API
Biotech API by Drug Type:
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Other Biotech APIs
Biotech API by Customer Base:
• Innovative Biologic API
• Generic Biosimilar API
Biotech API by Expression Technology:
• Mammalian Expression
• Microbial Expression
• Yeast Expression
• Insect Expression
• Other Expression Technologies
HPAPI
• Branded HPAPI
• Generic HPAPI

Based on Manufacturing Process, the North America market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.
Captive Manufacturing
• Branded Captive API
• Generic Captive API
Merchant Manufacturing by Drug Type:
• Branded Merchant API
• Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
• Merchant Synthetic API
• Merchant Biotech API

Based on Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications

Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs

Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue are available for 2017-2027. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America API market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 16
1.2.6 Market Size/Share Estimation 17
1.2.7 Research Limitations 18
1.3 Executive Summary 19
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter’s Fiver Forces Analysis 39
3 Segmentation of North America Market by Synthesis 43
3.1 Market Overview by Synthesis 43
3.2 Synthetic API 45
3.2.1 Branded Synthetic API 46
3.2.2 Generic Synthetic API 47
3.3 Biotech API 48
3.3.1 Biotech API by Drug Type 49
3.3.1.1 Monoclonal Antibodies 50
3.3.1.2 Recombinant Proteins 51
3.3.1.3 Vaccines 52
3.3.1.4 Other Biotech APIs 53
3.3.2 Biotech API by Customer Base 54
3.3.2.1 Innovative Biologic API 55
3.3.2.2 Generic Biosimilar API 56
3.3.3 Biotech API by Expression Technology 57
3.3.3.1 Mammalian Expression 58
3.3.3.2 Microbial Expression 59
3.3.3.3 Yeast Expression 60
3.3.3.4 Insect Expression 61
3.3.3.5 Other Expression Technologies 62
3.4 HPAPI 63
3.4.1 Branded HPAPI 64
3.4.2 Generic HPAPI 65
4 Segmentation of North America Market by Manufacturing Process 66
4.1 Market Overview by Manufacturing Process 66
4.2 Captive Manufacturing 68
4.2.1 Branded Captive API 69
4.2.2 Generic Captive API 70
4.3 Merchant Manufacturing 71
4.3.1 Merchant Manufacturing by Drug Type 72
4.3.1.1 Branded Merchant API 73
4.3.1.2 Generic Merchant API 74
4.3.2 Merchant Manufacturing by Drug Synthesis 75
4.3.2.1 Merchant Synthetic API 76
4.3.2.2 Merchant Biotech API 77
5 Segmentation of North America Market by Therapeutic Application 78
5.1 Market Overview by Therapeutic Application 78
5.2 Infectious Diseases 80
5.3 Oncology 81
5.4 Ophthalmology 82
5.5 Cardiovascular Disorders 83
5.6 Central Nervous System 84
5.7 Pulmonary Disorders 85
5.8 Orthopedics 86
5.9 Other Applications 87
6 Segmentation of North America Market by Drug Type 88
6.1 Market Overview by Drug Type 88
6.2 Branded Prescription Drugs 90
6.3 Generic Prescription Drugs 91
6.4 OTC Drugs 92
7 North America Market 2020-2027 by Country 93
7.1 Overview of North America Market 93
7.2 U.S. 96
7.3 Canada 100
7.4 Mexico 102
8 Competitive Landscape 104
8.1 Overview of Key Vendors 104
8.2 New Product Launch, Partnership, Investment, and M&A 107
8.3 Company Profiles 108
AbbVie Inc. 108
Astrazeneca 110
Aurobindo Pharma Ltd. 113
BASF 115
Bayer AG 118
Boehringer Ingelheim 120
Dr. Reddy's Laboratories 124
F. Hoffmann-La Roche 126
GlaxoSmithKline plc 128
Lonza Group 132
Lupin Limited 136
Merck & Co., Inc. 138
Mylan NV 140
Novartis International AG 142
Pfizer Inc. 144
Sanofi 148
Sun Pharmaceutical Industries Ltd. 150
Teva Pharmaceutical Industries Ltd. 152
9 Investing in North America Market: Risk Assessment and Management 155
9.1 Risk Evaluation of North America Market 155
9.2 Critical Success Factors (CSFs) 158
Related Reports and Products 161

List of Tables:

Table 1. Snapshot of North America Active Pharmaceutical Ingredients (API) Market in Balanced Perspective, 2020-2027 20
Table 2. Growth Rate of World Real GDP, 2017-2021 23
Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn 31
Table 4. Main Product Trends and Market Opportunities in North America Active Pharmaceutical Ingredients (API) Market 35
Table 5. North America Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 43
Table 6. North America Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2017-2027, $ bn 45
Table 7. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2017-2027, $ bn 49
Table 8. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Customer Base, 2017-2027, $ bn 54
Table 9. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2017-2027, $ bn 57
Table 10. North America Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2017-2027, $ bn 63
Table 11. North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 66
Table 12. North America Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2017-2027, $ bn 68
Table 13. North America Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2017-2027, $ bn 72
Table 14. North America Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2017-2027, $ bn 75
Table 15. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 78
Table 16. North America Active Pharmaceutical Ingredients (API) Market by Drug Type, 2017-2027, $ bn 88
Table 17. North America Active Pharmaceutical Ingredients (API) Market by Country, 2017-2027, $ bn 94
Table 18. U.S. Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 98
Table 19. U.S. Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 98
Table 20. U.S. Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 98
Table 21. Canada Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 101
Table 22. Canada Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 101
Table 23. Canada Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 101
Table 24. Mexico Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 103
Table 25. Mexico Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 103
Table 26. Mexico Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 103
Table 27. AbbVie Inc.: Company Snapshot 108
Table 28. AbbVie Inc.: Product Portfolio 108
Table 29. AbbVie Inc.: Revenue, 2017-2019, $ bn 109
Table 30. Astrazeneca: Company Snapshot 110
Table 31. Astrazeneca: Revenue, 2017-2019, $ bn 111
Table 32. Aurobindo Pharma Ltd.: Company Snapshot 113
Table 33. Aurobindo Pharma Ltd.: Product Portfolio 114
Table 34. Aurobindo Pharma Ltd.: Revenue, 2016-2020, $ INR million 114
Table 35. BASF: Company Snapshot 115
Table 36. BASF: Business Segmentation 116
Table 37. BASF: Revenue, 2016-2018, Euro million 116
Table 38. Bayer AG: Company Snapshot 118
Table 39. Bayer AG: Business Segmentation 119
Table 40. Bayer AG: Revenue, 2016-2018, € bn 119
Table 41. Bayer AG: Recent Developments 119
Table 42. Boehringer Ingelheim: Company Snapshot 120
Table 43. Boehringer Ingelheim: Business Segmentation in 2019 121
Table 44. Boehringer Ingelheim: Product Portfolio 121
Table 45. Boehringer Ingelheim: Revenue, 2017-2019, EUR million 122
Table 46. Boehringer Ingelheim: Revenue by Region in 2019 122
Table 47. Boehringer Ingelheim: Recent Developments 122
Table 48. Dr. Reddy's Laboratories: Company Snapshot 124
Table 49. Dr. Reddy's Laboratories: Business Segmentation 124
Table 50. Dr. Reddy's Laboratories: Revenue, 2018-2020, $ bn 125
Table 51. F. Hoffmann-La Roche: Company Snapshot 126
Table 52. AbbVie Inc.: Business Segmentation 126
Table 53. F. Hoffmann-La Roche: Revenue, 2017-2019, $ bn 127
Table 54. GlaxoSmithKline: Company Snapshot 128
Table 55. GlaxoSmithKline: Business Segmentation 129
Table 56. GlaxoSmithKline: Product Portfolio 130
Table 57. GlaxoSmithKline: Revenue, 2016-2018, $ bn 131
Table 58. GlaxoSmithKline: Recent Developments 131
Table 59. Lonza Group: Company Snapshot 132
Table 60. Lonza Group: Business Segmentation in 2018 133
Table 61. Lonza Group: Product Portfolio 133
Table 62. Lonza Group: Revenue, 2017-2019, $ billion 134
Table 63. Lonza Group: Revenue by Region in 2018 134
Table 64. Lonza Group: Recent Developments 135
Table 65. Lupin Limited: Company Snapshot 136
Table 66. Lupin Limited: Business Segmentation 136
Table 67. Lupin Limited: Revenue, 2016-2018, INR billion 137
Table 68. Merck & Co., Inc.: Company Snapshot 138
Table 69. Merck & Co., Inc.: Business Segmentation 138
Table 70. Merck & Co., Inc.: Revenue, 2017-2019, $ bn 139
Table 71. Mylan NV: Company Snapshot 140
Table 72. Mylan NV: Revenue, 2017-2019, $ bn 141
Table 73. Novartis International AG: Company Snapshot 142
Table 74. Novartis International AG: Business Segmentation 142
Table 75. Novartis International AG: Revenue, 2017-2019, $ bn 143
Table 76. Pfizer Inc.: Company Snapshot 144
Table 77. Pfizer Inc.: Business Segmentation 145
Table 78. Pfizer Inc.: Product Portfolio 145
Table 79. Pfizer Inc.: Revenue, 2016-2018, $ bn 146
Table 80. Pfizer Inc.: Recent Developments 146
Table 81. Sanofi: Company Snapshot 148
Table 82. Sanofi: Business Segmentation 148
Table 83. Sanofi: Revenue, 2017-2019, $ bn 149
Table 84. Sun Pharmaceutical Industries Limited: Company Snapshot 150
Table 85. Sun Pharmaceutical Industries Limited: Revenue, 2017-2019, INR bn 151
Table 86. Teva Pharmaceutical Industries Ltd.: Company Snapshot 152
Table 87. Teva Pharmaceutical Industries Ltd.: Business Segmentation 153
Table 88. Teva Pharmaceutical Industries Ltd.: Revenue, 2017-2019, $ bn 153
Table 89. Risk Evaluation for Investing in North America Market, 2020-2027 156
Table 90. Critical Success Factors and Key Takeaways 159

 

 

List of Figures:

Figure 1. Research Method Flow Chart 13
Figure 2. Breakdown of Primary Research 15
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 17
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 19
Figure 5. North America Active Pharmaceutical Ingredients (API) Market, 2020-2027, $ bn 21
Figure 6. Impact of COVID-19 on Business 25
Figure 7. Primary Drivers and Impact Factors of North America Active Pharmaceutical Ingredients (API) Market 27
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 30
Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 10. Primary Restraints and Impact Factors of North America Active Pharmaceutical Ingredients (API) Market 32
Figure 11. Investment Opportunity Analysis 36
Figure 12. Porter’s Fiver Forces Analysis of North America Active Pharmaceutical Ingredients (API) Market 39
Figure 13. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Synthesis, 2020-2027, % of Revenue 43
Figure 14. Contribution to North America 2021-2027 Cumulative Revenue by Synthesis, Value ($ bn) and Share (%) 44
Figure 15. North America Active Pharmaceutical Ingredients (API) Market: Synthetic API, 2017-2027, $ bn 45
Figure 16. North America Active Pharmaceutical Ingredients (API) Market: Branded Synthetic API, 2017-2027, $ bn 46
Figure 17. North America Active Pharmaceutical Ingredients (API) Market: Generic Synthetic API, 2017-2027, $ bn 47
Figure 18. North America Active Pharmaceutical Ingredients (API) Market: Biotech API, 2017-2027, $ bn 48
Figure 19. North America Active Pharmaceutical Ingredients (API) Market: Monoclonal Antibodies, 2017-2027, $ bn 50
Figure 20. North America Active Pharmaceutical Ingredients (API) Market: Recombinant Proteins, 2017-2027, $ bn 51
Figure 21. North America Active Pharmaceutical Ingredients (API) Market: Vaccines, 2017-2027, $ bn 52
Figure 22. North America Active Pharmaceutical Ingredients (API) Market: Other Biotech APIs, 2017-2027, $ bn 53
Figure 23. North America Active Pharmaceutical Ingredients (API) Market: Innovative Biologic API, 2017-2027, $ bn 55
Figure 24. North America Active Pharmaceutical Ingredients (API) Market: Generic Biosimilar API, 2017-2027, $ bn 56
Figure 25. North America Active Pharmaceutical Ingredients (API) Market: Mammalian Expression, 2017-2027, $ bn 58
Figure 26. North America Active Pharmaceutical Ingredients (API) Market: Microbial Expression, 2017-2027, $ bn 59
Figure 27. North America Active Pharmaceutical Ingredients (API) Market: Yeast Expression, 2017-2027, $ bn 60
Figure 28. North America Active Pharmaceutical Ingredients (API) Market: Insect Expression, 2017-2027, $ bn 61
Figure 29. North America Active Pharmaceutical Ingredients (API) Market: Other Expression Technologies, 2017-2027, $ bn 62
Figure 30. North America Active Pharmaceutical Ingredients (API) Market: HPAPI, 2017-2027, $ bn 63
Figure 31. North America Active Pharmaceutical Ingredients (API) Market: Branded HPAPI, 2017-2027, $ bn 64
Figure 32. North America Active Pharmaceutical Ingredients (API) Market: Generic HPAPI, 2017-2027, $ bn 65
Figure 33. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2020-2027, % of Revenue 66
Figure 34. Contribution to North America 2021-2027 Cumulative Revenue by Manufacturing Process, Value ($ bn) and Share (%) 67
Figure 35. North America Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing, 2017-2027, $ bn 68
Figure 36. North America Active Pharmaceutical Ingredients (API) Market: Branded Captive API, 2017-2027, $ bn 69
Figure 37. North America Active Pharmaceutical Ingredients (API) Market: Generic Captive API, 2017-2027, $ bn 70
Figure 38. North America Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing, 2017-2027, $ bn 71
Figure 39. North America Active Pharmaceutical Ingredients (API) Market: Branded Merchant API, 2017-2027, $ bn 73
Figure 40. North America Active Pharmaceutical Ingredients (API) Market: Generic Merchant API, 2017-2027, $ bn 74
Figure 41. North America Active Pharmaceutical Ingredients (API) Market: Merchant Synthetic API, 2017-2027, $ bn 76
Figure 42. North America Active Pharmaceutical Ingredients (API) Market: Merchant Biotech API, 2017-2027, $ bn 77
Figure 43. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2020-2027, % of Revenue 78
Figure 44. Contribution to North America 2021-2027 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 79
Figure 45. North America Active Pharmaceutical Ingredients (API) Market: Infectious Diseases, 2017-2027, $ bn 80
Figure 46. North America Active Pharmaceutical Ingredients (API) Market: Oncology, 2017-2027, $ bn 81
Figure 47. North America Active Pharmaceutical Ingredients (API) Market: Ophthalmology , 2017-2027, $ bn 82
Figure 48. North America Active Pharmaceutical Ingredients (API) Market: Cardiovascular Disorders, 2017-2027, $ bn 83
Figure 49. North America Active Pharmaceutical Ingredients (API) Market: Central Nervous System, 2017-2027, $ bn 84
Figure 50. North America Active Pharmaceutical Ingredients (API) Market: Pulmonary Disorders, 2017-2027, $ bn 85
Figure 51. North America Active Pharmaceutical Ingredients (API) Market: Orthopedics, 2017-2027, $ bn 86
Figure 52. North America Active Pharmaceutical Ingredients (API) Market: Other Applications, 2017-2027, $ bn 87
Figure 53. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Drug Type, 2020-2027, % of Revenue 88
Figure 54. Contribution to North America 2021-2027 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 89
Figure 55. North America Active Pharmaceutical Ingredients (API) Market: Branded Prescription Drugs, 2017-2027, $ bn 90
Figure 56. North America Active Pharmaceutical Ingredients (API) Market: Generic Prescription Drugs, 2017-2027, $ bn 91
Figure 57. North America Active Pharmaceutical Ingredients (API) Market: OTC Drugs, 2017-2027, $ bn 92
Figure 58. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Country, 2020 and 2027, % of Revenue 94
Figure 59. Contribution to North America 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%) 95
Figure 60. U.S. Active Pharmaceutical Ingredients (API) Market, 2017-2027, $ bn 97
Figure 61. Canada Active Pharmaceutical Ingredients (API) Market, 2017-2027, $ bn 100
Figure 62. Active Pharmaceutical Ingredients (API) Market in Mexico, 2017-2027, $ bn 102
Figure 63. Growth Stage of North America Active Pharmaceutical Ingredients (API) Industry over the Forecast Period 104
Figure 64. Top products of AstraZeneca based on revenue from 2016 to 2019 (in million U.S. dollars) 111

 

Reviews

There are yet no reviews for this product.